Potential viral therapy weapon for difficult cancers is safe and effectiv...(hat combinations with other treatments. ...),Health
Navigation Links
Potential viral therapy weapon for difficult cancers is safe and effective in study
Date:4/22/2008
hat combinations with other treatments.
'/>"/>
| Contact: Nick Miller 513-803-6035 Cincinnati Children's Hospital Medical Center Source:Eurekalert |
Related medicine news :
1. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
2. Minnesota partnership advances potential MS therapy
3. Toxic Stock Syndrome Report: Many Companies Are Keeping Shareholders in the Dark on Potential Recalls, Bans, and Other Risks
4. A potential sugar fix for tumors
5. Potential blood test for chronic sinusitis identified
6. Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study
7. Stem cell research leads to potential new therapy for rare blood disorder
8. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
9. Angina drug potentially useful against heart rhythm disorders
10. Neuronal regulators offer potential targets for cancer
11. Companies Not Fully Tapping Potential of Onsite Health Centers
Post Your Comments:
Breaking Medicine News(10 mins):Health News:The Logo Loft Hires Laid-Off Sales Executive Increasing Sales for Company by 15% Despite the Recession 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:Life Science And Medical Device Software Engineering Consulting Firm Full Spectrum Software Announces 12 New Contract Wins In 2009 2Health News:Unanimous Vote Creates Largest RN Union in U.S. History 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5
[0] The Logo Loft Hires Laid-Off Sales Executive Increasing Sales for Company by 15% Despite the Recession[0] Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative[0] Life Science And Medical Device Software Engineering Consulting Firm Full Spectrum Software Announces 12 New Contract Wins In 2009[0] Unanimous Vote Creates Largest RN Union in U.S. History[1] Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
Other Medicine News:Health News:Europe Faces Threat Of Rise In Infectious Diseases 2Health News:Complete Ban on Fizzy Drinks in Schools 2
Breakthrough In The Identity Of Compounds That Encourage Stem Cell GrowthAgricultural Subsidies Responsible For Obesity, Says ExpertEurope Faces Threat Of Rise In Infectious DiseasesPregnant HIV Positive Woman Forced To Abort Fetus On Her OwnCured Meat may be Harmful to LungsComplete Ban on Fizzy Drinks in Schools
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Aware Inc Reports Third Quarter 2009 Financial Results 10445 1Aware Inc Reports Third Quarter 2009 Financial Results 10445 2Aware Inc Reports Third Quarter 2009 Financial Results 10445 3Aware Inc Reports Third Quarter 2009 Financial Results 10445 4Aware Inc Reports Third Quarter 2009 Financial Results 10445 5Aware Inc Reports Third Quarter 2009 Financial Results 10445 6Aware Inc Reports Third Quarter 2009 Financial Results 10445 7Fish Oil Supplements Dont Help Depressed Heart Patients 59851 1Fish Oil Supplements Dont Help Depressed Heart Patients 59851 2Fish Oil Supplements Dont Help Depressed Heart Patients 59851 3Depression in older cancer patients can be effectively treated with collaborative approach 59848 1Depression in older cancer patients can be effectively treated with collaborative approach 59848 2Depression in older cancer patients can be effectively treated with collaborative approach 59848 3
[0] Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease[0] Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million[0] Hill-Rom Announces Appointment of James R. Giertz to Board of Directors
Other Medicine Technology:Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 3Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 4Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 2Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |